Ionis Pharmaceuticals, Inc.
IONS
$32.96
$0.060.18%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -30.18% | -7.21% | 19.55% | -8.45% | 113.65% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -30.18% | -7.21% | 19.55% | -8.45% | 113.65% |
| Cost of Revenue | -3.97% | 1.52% | -2.68% | 8.64% | -16.78% |
| Gross Profit | -135.05% | -18.69% | 97.78% | -41.14% | 140.54% |
| SG&A Expenses | 72.67% | -11.88% | 41.11% | 15.66% | 6.38% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 8.62% | -1.74% | 4.57% | 9.95% | -13.69% |
| Operating Income | -898.61% | -3.76% | 26.72% | -30.98% | 106.67% |
| Income Before Tax | -3,768.41% | -2.34% | 14.52% | -26.37% | 93.76% |
| Income Tax Expenses | -141.41% | -154.85% | -99.18% | -99.34% | -19.80% |
| Earnings from Continuing Operations | -1,026.51% | 4.70% | 22.31% | -14.86% | 82.33% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -1,026.51% | 4.70% | 22.31% | -14.86% | 82.33% |
| EBIT | -898.61% | -3.76% | 26.72% | -30.98% | 106.67% |
| EBITDA | -733.19% | -3.99% | 27.53% | -31.90% | 108.35% |
| EPS Basic | -927.06% | 8.09% | 23.83% | -12.65% | 82.58% |
| Normalized Basic EPS | -642.26% | -0.69% | 21.41% | -26.57% | 108.25% |
| EPS Diluted | -927.06% | 8.09% | 23.83% | -12.65% | 82.58% |
| Normalized Diluted EPS | -642.26% | -0.69% | 21.41% | -26.57% | 108.25% |
| Average Basic Shares Outstanding | 9.72% | 3.68% | 2.00% | 1.96% | 1.41% |
| Average Diluted Shares Outstanding | 9.72% | 3.68% | 2.00% | 1.96% | 1.41% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
